Reimbursement ChallengesThe surgical glaucoma business is expected to face headwinds through the remainder of the year, which management acknowledged is not something it can grow through until potentially the fourth quarter.
Sales GuidanceManagement reiterated full-year sales guidance of a 6% to 12% decline year-over-year, indicating ongoing challenges.
Tariffs ImpactTariffs are expected to be a ~$4M headwind, but management has begun to transition manufacturing outside of China over the next 9+ months.